The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute
Abstract
Purpose: Molecular tumor profiling is a promising diagnostic technique to determine the tissue of origin in patients with carcinoma of unknown primary site (CUP). However, the clinical value of these molecular predictions is unknown. We used tumor profiling results to direct site-specific therapy for patients with CUP. Patients and Methods: Tumor biopsy specimens from previously untreated patients with CUP were tested with a 92-gene reverse transcriptase polymerase chain reaction cancer classification assay. When a tissue of origin was predicted, patients who were treatment candidates received standard site-specific first-line therapy. Results: Of 289 patients enrolled, 252 had successful assays performed, and 247 (98%) had a tissue of origin predicted. Sites most commonly predicted were biliary tract (18%), urothelium (11%), colorectal (10%), and non–small-cell lung (7%). Two hundred twenty-three patients were treatment candidates, and 194 patients received assay-directed site-specific treatment. In these 194 patients, the median survival time was 12.5 months (95% CI, 9.1 to 15.4 months). When the assay predicted tumor types that were clinically more responsive, the median survival was significantly improved when compared with predictions of more resistant tumors (13.4 v 7.6 months, respectively; P = .04). Conclusion: In this large prospective trial, molecular tumor profiling predicted a tissue of origin in most patients with CUP. The median survival time of 12.5 months for patients who received assay-directed site-specific therapy compares favorably with previous results using empiric CUP regimens. Patients with CUP predicted to have more responsive tumor types had longer survival compared with patients with less responsive tumor types. Molecular tumor profiling contributes to the management of patients with CUP and should be a part of their standard evaluation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Self-citationCancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
Escudier, B., Bellmunt, J., Négrier, S., Bajetta, E., Melichar, B., Bracarda, S., Ravaud, A., Golding, S., Jethwa, S., & Sneller, V. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7849 · Cited by 800
Cancer of unknown primary site
Pavlidis, N., & Pentheroudakis, G. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61178-1 · Cited by 584
Fizazi, K., Greco, F. A., Pavlidis, N., Daugaard, G., Oien, K., & Pentheroudakis, G. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv305 · Cited by 453
Self-citationMolecular Profiling of Carcinoma of Unknown Primary and Correlation With Clinical Evaluation
Varadhachary, G. R., Talantov, D., Raber, M. N., Meng, C., Hess, K. R., Jatkoe, T., Lenzi, R., Spigel, D. R., Wang, Y., Greco, F. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4378 · Cited by 234
Self-citationMa, X.-J., Patel, R., Wang, X., Salunga, R., Murage, J., Desai, R., Tuggle, J. T., Wang, W., Chu, S., Stecker, K., et al. (2006) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2006-130-465-mcohcu · Cited by 212
Horlings, H. M., van Laar, R. K., Kerst, J.-M., Helgason, H. H., Wesseling, J., van der Hoeven, J. J. M., Warmoes, M. O., Floore, A., Witteveen, A., Lahti-Domenici, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.6969 · Cited by 184
Culine, S., Lortholary, A. H., Voigt, J., Bugat, R., Théodore, C., Priou, F., Kaminsky, M., Lesimple, T., Pivot, X. B., Coudert, B. P., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.104 · Cited by 157
Molecular Profiling in Unknown Primary Cancer: Accuracy of Tissue of Origin Prediction
Greco, F. A., Spigel, D. R., Yardley, D. A., Erlander, M. G., Ma, X., & Hainsworth, J. D. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0328 · Cited by 129
Self-citation
Cited by
Hoadley, K. A., Yau, C., Hinoue, T., Wolf, D. M., Lazar, A. J., Drill, E., Shen, R., Taylor, A. M., Cherniack, A. D., Thorsson, V., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.022 · Cited by 2,546
“Using either RNA (Hainsworth et al., 2013) or DNA methylation (Moran et al.”
BackgroundSelf-citationZamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Cholangiocarcinoma — evolving concepts and therapeutic strategies
Ilyas, S. I., Khan, S. A., Hallemeier, C. L., Kelley, R. K., & Gores, G. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.157 · Cited by 1,626
Valle, J. W., Kelley, R. K., Nervi, B., Oh, D.-Y., & Zhu, A. X. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00153-7 · Cited by 1,043
Brindley, P. J., Bachini, M., Ilyas, S. I., Khan, S. A., Loukas, A., Sirica, A. E., Teh, B. T., Wongkham, S., & Gores, G. J. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00300-2 · Cited by 841
Metadata
- Authors
- Hainsworth, J. D., Rubin, M. S., Spigel, D. R., Boccia, R. V., Raby, S., Quinn, R., & Greco, F. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-01-10
- Volume
- 31
- Issue
- 2
- Pages
- 217-223
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2161179758
- Cited by
- 362
- References
- 17
- FWCI
- 12.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute. https://app.cochat.ai/papers/10.1200/jco.2012.43.3755
- The paper
- Hainsworth, J. D., Rubin, M. S., Spigel, D. R., Boccia, R. V., Raby, S., Quinn, R., & Greco, F. A. (2013). Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2012.43.3755
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.